These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

141 related articles for article (PubMed ID: 7712676)

  • 1. Orocecal transit time in humans assessed by sulfapyridine appearance in saliva after sulfasalazine intake.
    Dhôte R; Bergmann JF; Leglise P; Chassany O; Elkharrat D; Conort O; Caulin C
    Clin Pharmacol Ther; 1995 Apr; 57(4):461-70. PubMed ID: 7712676
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The variability of orocecal transit time evaluated by the salicylazosulphapyridine/sulphapyridine method.
    Gramatté T; Terhaag B
    Int J Clin Pharmacol Ther Toxicol; 1991 Apr; 29(4):147-50. PubMed ID: 1676990
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Time course of free and N4-acetylated sulfapyridine concentrations in the plasma and saliva of man after sulfasalazine (salicylazosulfapyridine) administration: preliminary findings.
    Bates TR; Blumenthal HP; Pieniaszek HJ
    Res Commun Chem Pathol Pharmacol; 1976 Sep; 15(1):183-9. PubMed ID: 9675
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Oro-caecal transit time in man assessed by the sulfasalazine/sulfapyridine test. Correlation between plasma-saliva appearance of sulfapyridine.
    Dhôte R; Leglise P; Bergmann JF; Conort O; Caulin C
    Fundam Clin Pharmacol; 1992; 6(8-9):383-5. PubMed ID: 1363408
    [No Abstract]   [Full Text] [Related]  

  • 5. [Comparative effects of ricinoleic acid and senna on orocecal and oroanal transit time in healthy subjects. Application of the salacylazosulfapyridine method].
    Sogni P; Chaussade S; Akue-Gohe K; Nepveux P; Homerin M; Couturier D; Guerre J
    Gastroenterol Clin Biol; 1992; 16(1):21-4. PubMed ID: 1347025
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Salivary excretion and pharmacokinetics of sulfapyridine after sulfasalazine.
    Bates TR; Blumenthal HP; Pieniaszek HJ
    Clin Pharmacol Ther; 1977 Dec; 22(6):917-27. PubMed ID: 21768
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Relationship between the acetylator phenotype, plasma sulfapyridine levels and adverse effects during treatment with salicylazosulfapyridine in patients with chronic bowel diseases.
    Rahav G; Zylber-Katz E; Rachmilewitz D; Levy M
    Isr J Med Sci; 1990 Jan; 26(1):31-4. PubMed ID: 1968894
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Influence of age and body size on orocecal transit time as assessed by use of the sulfasalazine method in healthy dogs.
    Weber MP; Martin LJ; Biourge VC; Nguyen PG; Dumon HJ
    Am J Vet Res; 2003 Sep; 64(9):1105-9. PubMed ID: 13677387
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effect of food on gastrointestinal transit of liquids in cynomolgus monkeys.
    Kondo H; Watanabe T; Yokohama S; Watanabe J
    Biopharm Drug Dispos; 2003 May; 24(4):141-51. PubMed ID: 12698497
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Saliva: plasma concentration relationships for sulphapyridine following sulphasalazine administration to normal volunteers and patients with inflammatory bowel disease.
    Day JM; Houston JB
    Br J Clin Pharmacol; 1980 Jan; 9(1):91-4. PubMed ID: 6101957
    [No Abstract]   [Full Text] [Related]  

  • 11. Bloating and distension in irritable bowel syndrome: the role of gastrointestinal transit.
    Agrawal A; Houghton LA; Reilly B; Morris J; Whorwell PJ
    Am J Gastroenterol; 2009 Aug; 104(8):1998-2004. PubMed ID: 19491831
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Relative systemic availability of sulfapyridine from commercial enteric-coated and uncoated sulfasalazine tablets.
    Pieniaszek HJ; Resetarits DE; Wilferth WW; Blumenthal HP; Bates TR
    J Clin Pharmacol; 1979 Jan; 19(1):39-45. PubMed ID: 33201
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Influence of alcohol on gastrointestinal motility: lactulose breath hydrogen testing in orocecal transit time in chronic alcoholics, social drinkers and teetotaler subjects.
    Addolorato G; Montalto M; Capristo E; Certo M; Fedeli G; Gentiloni N; Stefanini GF; Gasbarrini G
    Hepatogastroenterology; 1997; 44(16):1076-81. PubMed ID: 9261602
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Sulfapyridine appearance in plasma after salicylazosulfapyridine. Another simple measure of intestinal transit.
    Kellow JE; Borody TJ; Phillips SF; Haddad AC; Brown ML
    Gastroenterology; 1986 Aug; 91(2):396-400. PubMed ID: 2873075
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of codeine on gastrointestinal motility in relation to CYP2D6 phenotype.
    Mikus G; Trausch B; Rodewald C; Hofmann U; Richter K; Gramatté T; Eichelbaum M
    Clin Pharmacol Ther; 1997 Apr; 61(4):459-66. PubMed ID: 9129563
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A comparison of orocaecal transit times assessed by the breath hydrogen test and the sulphasalazine/sulphapyridine method in healthy beagle dogs.
    Papasouliotis K; Gruffydd-Jones TJ; Sparkes AH; Cripps PJ
    Res Vet Sci; 1995 May; 58(3):263-7. PubMed ID: 7659853
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Modification of orocecal transit time of salazosulfapyridine by atropine and metoclopramide in healthy probands].
    Terhaag B; Neugebauer A
    Dtsch Z Verdau Stoffwechselkr; 1986; 46(6):327-32. PubMed ID: 2881772
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Using pharmacokinetic modeling to determine the effect of drug and food on gastrointestinal transit in dogs.
    Sjödin L; Visser S; Al-Saffar A
    J Pharmacol Toxicol Methods; 2011; 64(1):42-52. PubMed ID: 21596146
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effect of clonidine on gastrointestinal transit time.
    Mann NS; Shinkle JM
    Hepatogastroenterology; 1998; 45(22):1023-5. PubMed ID: 9756001
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Sluggish small bowel motility is involved in determining increased biliary deoxycholic acid in cholesterol gallstone patients.
    Azzaroli F; Mazzella G; Mazzeo C; Simoni P; Festi D; Colecchia A; Montagnani M; Martino C; Villanova N; Roda A; Roda E
    Am J Gastroenterol; 1999 Sep; 94(9):2453-9. PubMed ID: 10484008
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.